Now showing items 1-4 of 4

    • Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. 

      Allott, L; Da Pieve, C; Meyers, J; Spinks, T; Ciobota, DM; Kramer-Marek, G; Smith, G (2017-07-27)
      The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule ...
    • Mapping the 3D structures of small molecule binding sites 

      Meyers, J; Brown, N; Blagg, J (2016-12-06)
    • On the origins of three-dimensionality in drug-like molecules. 

      Meyers, J; Carter, M; Mok, NY; Brown, N (2016-09)
      Many medicinal chemistry-relevant structures and core scaffolds tend toward geometric planarity, which hampers the optimization of physicochemical properties desirable in drug-like molecules. As challenging drug target ...
    • Privileged Structures and Polypharmacology within and between Protein Families. 

      Meyers, J; Chessum, NEA; Ali, S; Mok, NY; Wilding, B; Pasqua, AE; Rowlands, M; Tucker, MJ; Evans, LE; Rye, CS; O'Fee, L; Le Bihan, Y-V; Burke, R; Carter, M; Workman, P; Blagg, J; Brown, N; van Montfort, RLM; Jones, K; Cheeseman, MD (2018-12-13)
      Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 (1) and the pirin ...